Pharmacogenetics in Primary Care Psychotropics

University of Arizona

Status and phase: Unknown; Phase 3

Conditions: Obsessive-Compulsive Disorder; Generalized Anxiety Disorder; Depression

Treatments: Diagnostic Test: Pharmacogenetic testing

Study type: Interventional

Funder types: Other

Identifiers

NCT03232502

Pending1

Details and patient eligibility

About

Pragmatic trial of pharmacogenetic testing at the time of prescription for a selective serotonin reuptake inhibitor, tricyclic antidepressant or atypical antipsychotic. Does real time intervention improve patient outcomes?

Enrollment: 130 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Over 18
• Prescribed a drug of interest for the first time

Exclusion criteria

• Previous pharmacogenetic testing available

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

130 participants in 2 patient groups

Control

No Intervention group

Intervention

Experimental group

Treatment:

Diagnostic Test: Pharmacogenetic testing